lti-03
lti-03: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Rein Therapeutics, Inc. (RNTX) | Phase 2 |
Clinical Trials (1)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability and Efficacy of Caveolin-1-Scaffolding-Protein-Derived Peptide (LTI-03) in Patients With Idiopathic Pulmonary Fibrosis
FDA Decisions
FDA_MeetingFDA agreed MCH/H findings in GLP rat studies are not dose-limiting; confirmed no new GLP toxicity study required for CRL submission.(RNTX)
Frequently asked questions
Who is developing lti-03?
lti-03 is being developed by Rein Therapeutics, Inc..
How many clinical trials involve lti-03?
BioSniper tracks 1 clinical trial involving lti-03.
What is lti-03's latest FDA decision?
The most recent tracked FDA decision for lti-03 is FDA_Meeting for FDA agreed MCH/H findings in GLP rat studies are not dose-limiting; confirmed no new GLP toxicity study required for CRL submission., dated September 16, 2025.
Get deeper analysis on lti-03
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis